Under the agreement, Bayer will support the further
development, supply and key territory operations of CureVac´s COVID-19 vaccine.
Dr. Franz-Werner Haas, the chief executive officer of
CureVac, sad they were happy to join forces with Bayer, and that its “expertise
and infrastructure will help us make our vaccine candidate CVnCoV even more
rapidly available to as many people as possible."
“Building on the positive data we have seen so far with
CVnCoV, we now also have another strong partner on our side to get the vaccine
to the people who need it following the receipt of the requisite regulatory
approvals,” he said.
Last month, CureVac launched the final stage of clinical
trials of its potential coronavirus vaccine. If the trials are successful, it
will become the second German firm to develop a COVID-19 vaccine after BioNTech
(in partnership with US pharma giant Pfizer).
Coronavirus vaccination campaign has begun in EU states, the
US, UK, China and Russia, among others.
More than 15.5 million doses have been administered in at
least 46 countries, according to Our World in Data, a global tracking website
affiliated with Oxford University.
Over 367,000 people have so far been inoculated in Germany,
which started the immunization drive on Dec. 27 last year.
0 comments:
Post a Comment